olivLaw · US equity research
Bio Green Med Solution, Inc. BGMS
Wholesale-Durable Goods, NEC · SIC 5099 · Vertical: Wholesale — durable goods (SIC 509x)
Bio Green Med Solution, Inc. (BGMS), formerly a biopharmaceutical company, now operates through Fitters Sdn. Bhd. in Malaysia, distributing fire protection equipment. The company still carries limited capital and a going concern warning, and a merger with Future NRG Sdn. Bhd. could substantially change its structure. Revenues remain modest, at 0.7 million dollars for the period from acquisition to year-end 2025.
At the close of 05 Nov 2026, Bio Green Med Solution, Inc. (BGMS) stock was 0.87 USD (−3.89% on the day), with market capitalisation 5.7 m USD, beta 0.65, 52-week range 0.60–1.82 USD. Latest reported quarter (Q2 2026): revenue of 336.0 k USD, net income of -405.0 k USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 45.9
- neutral
- Bollinger (20, 2)
- 0.82 – 1.00
- in the lower half of the band · %B 0.25 · band width 20.2%
- SMA 50 / 200
- 0.90 / 0.97
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.01 / 0.00
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −0.6% | −1.1% | +0.5 pp | — |
| 3 months | −10.8% | −0.5% | −10.4 pp | — |
| 6 months | −12.6% | +4.4% | −17.0 pp | — |
| Year to date | −41.6% | +12.3% | −53.9 pp | — |
| 1 year | −47.6% | +13.5% | −61.1 pp | −36.6% |
| 3 years | −100.0% | +76.4% | −176.4 pp | +30.9% |
| 5 years | −100.0% | +63.7% | −163.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.0 k | 0 | — | — | 81.0 k | -81.0 k | 743.0 k | 336.0 k |
| Research & development | 950.0 k | 880.0 k | 822.0 k | 68.0 k | 5.0 k | -47.0 k | — | — |
| SG&A | 1.2 m | 948.0 k | — | — | — | — | — | — |
| Operating income | -2.2 m | -1.8 m | -4.2 m | -1.2 m | -992.0 k | -1.1 m | -246.0 k | -418.0 k |
| Pre-tax income | -2.2 m | -1.9 m | -4.2 m | -1.2 m | -988.0 k | -606.0 k | -167.0 k | -396.0 k |
| Income tax | -210.0 k | 1.2 m | — | 2.0 k | 0 ≈ | 5.0 k | 30.0 k | 9.0 k |
| Net income | -2.0 m | -3.1 m | -81.0 k | -1.3 m | -988.0 k | -611.0 k | -197.0 k | -405.0 k |
| Diluted EPS | -43.80 | -77.87 ≈ | 0.00 | -0.98 | -1.31 | -0.13 ≈ | — | — |
| Operating cash flow | -3.1 m ≈ | -1.4 m | -3.2 m | -1.1 m ≈ | -434.0 k ≈ | -33.0 k | -278.0 k | -352.0 k ≈ |
| Capex | 0 ≈ | — | — | — | — | — | 1.0 k | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ⚠ 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 150.0 k | unavailable | 0 | 0 | 0 | 420.0 k | 43.0 k | 0 |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | — | −100.0% |
| Net income | -7.3 m | -7.8 m | -8.4 m | -18.5 m | -21.2 m | -22.6 m | -11.2 m | -3.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | — | unavailable |
| Diluted EPS | unavailable | unavailable | -3.42 | -2.09 | -27.24 | -6,419.18 | -502.46 | -6.45 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | — | unavailable |
| net % | -4,858.7% | unavailable | unavailable | unavailable | unavailable | -5,370.2% | -26,074.4% | unavailable |
| Free cash flow | -6.7 m | -9.5 m | -8.0 m | -18.6 m | -20.8 m | -16.1 m | unavailable | unavailable |
The series breaks before 2024: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 3.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 6.8 m USD
- Total assets
- 8.2 m USD
- Debt / equity
- unavailable
- Current ratio
- 4.70x
- ROE
- unavailable
- ROA
- -48.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 420.0 k | 43.0 k | 0 | SEC (XBRL)· 30 Mar 2026verified |
| Research & development | 4.8 m | 14.9 m | 20.3 m | 19.2 m | 6.7 m | 848.0 k | SEC (XBRL)· 30 Mar 2026verified |
| SG&A | 5.9 m | 7.5 m | 7.4 m | 6.7 m | 5.4 m | — | SEC (XBRL)· 02 Apr 2025verified |
| Operating income | -10.6 m | -22.4 m | -27.7 m | -25.5 m | -12.0 m | -8.4 m | SEC (XBRL)· 30 Mar 2026verified |
| Depreciation & amortisation | 20.0 k | — | — | — | — | — | SEC (XBRL)· 01 Mar 2021verified |
| EBITDA | -10.6 m ≈ | — | — | — | — | — | SEC (XBRL)· 01 Mar 2021derived |
| Pre-tax income | -9.7 m | -22.2 m | -25.9 m | -25.6 m | -12.0 m | -3.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Income tax | -1.2 m | -3.7 m | -4.7 m | -3.0 m | -782.0 k | 7.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Net income | -8.4 m | -18.5 m | -21.2 m | -22.6 m | -11.2 m | -3.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Diluted EPS | -3.42 | -2.09 | -27.24 | -6,419.18 | -502.46 | -6.45 | SEC (XBRL)· 30 Mar 2026verified |
| Weighted average diluted shares | 3.6 m | 8.9 m | 11.3 m | 3.5 m | 22.3 k | 2.2 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 33.4 m | 36.6 m | 18.3 m | 3.4 m | 3.1 m | 3.5 m | SEC (XBRL)· 30 Mar 2026verified |
| Receivables | — | — | — | — | — | 1.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Inventories | — | — | — | — | — | 1.4 m | SEC (XBRL)· 30 Mar 2026verified |
| Current assets | 35.5 m | 40.9 m | 24.4 m | 7.4 m | 3.7 m | 6.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Property, plant & equipment, net | 106.0 k | 64.0 k | 32.0 k | 9.0 k | 3.0 k | 137.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Goodwill | — | — | — | — | — | 1.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Total assets | 36.8 m | 43.1 m | 28.1 m | 8.8 m | 4.1 m | 8.2 m | SEC (XBRL)· 30 Mar 2026verified |
| Accounts payable | 514.0 k | 2.1 m | 2.6 m | 3.5 m | 4.6 m | 617.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Current liabilities | 2.5 m | 5.4 m | 7.5 m | 8.2 m | 6.3 m | 1.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Total liabilities | 3.5 m | 5.4 m | 7.6 m | 8.2 m | 6.3 m | 1.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Equity | 33.3 m † | 37.7 m † | 15.9 m † | 607.0 k | -2.2 m | 6.8 m † | SEC (XBRL)· 30 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.9 m | -18.5 m | -20.8 m | -16.1 m | -8.0 m | -4.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Capex | 96.0 k | 27.0 k | 7.0 k | 6.0 k | — | — | SEC (XBRL)· 21 Mar 2024verified |
| Free cash flow | -8.0 m ≈ | -18.6 m ≈ | -20.8 m ≈ | -16.1 m ≈ | — | — | SEC (XBRL)· 21 Mar 2024derived |
| Investing cash flow | -96.0 k | -27.0 k | -7.0 k | -6.0 k | — | — | SEC (XBRL)· 21 Mar 2024verified |
| Financing cash flow | 29.5 m | 21.7 m | 3.0 m | 848.0 k | 7.8 m | 5.3 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 10.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 5.7 m USD
Key indicators
Coverage and freshness
Score by group
10% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -204.0% | 14 (vs peers) | 60% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 8.6x | 100 (on a fixed band) | 40% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial14/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Bio Green Med Solution, Inc. (BGMS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; YoY growth -100.0%; net margin -204.0%; ROE -40.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 8.6x
What contradicts it
- Net margin: -204.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Wholesale — durable goods (SIC 509x) · same industry group (3-digit SIC) · compared with 7 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| POOLPool Corporation | 7.7 bn | 19.9 | 30.4% | 7.3% | −0.4% | −11% / −38% |
| GOLDGold.com, Inc. | 1.1 bn | 12.4 | 10.8% | 0.3% | +132.4% | +31% / +31% |
| AENTAlliance Entertainment Holding Corporation | 216.5 m | 16.3 | 11.9% | 483.6% | 0.0% | −37% / +347% |
| SORAAsiaStrategy | 57.9 m | 4.6 | 106.1% | 111.9% | −37.7% | −40% / unavailable |
| BGMSBio Green Med Solution, Inc. | 5.7 m | — | -40.8% | -204.0% | −100.0% | −48% / −100% |
| GNLNGreenlane Holdings, Inc. | 847.3 k | — | -534.0% | -4,630.6% | −67.2% | −95% / −100% |
| YDDLOne and one Green Technologies. INC | — | 4.5 | 37.8% | 17.9% | +23.1% | −80% / unavailable |
| CNMCore & Main, Inc. | — | 19.4 | 23.4% | 6.0% | +2.8% | −3% / +34% |
1- and 3-year price returns: for BGMS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Bio Green Med Solution, Inc. (BGMS), formerly a biopharmaceutical company, now operates through Fitters Sdn. Bhd. in Malaysia, distributing fire protection equipment. The company still carries limited capital and a going concern warning, and a merger with Future NRG Sdn. Bhd. could substantially change its structure. Revenues remain modest, at 0.7 million dollars for the period from acquisition to year-end 2025 1.
SWOT
Strengths
- The company has a presence of several decades in fire equipment distribution through Fitters, with locally recognised certifications 1.
- The Malaysian operation benefits from a growing market and a regulatory framework that requires certified equipment 1.
- The company reports no reliance on institutional bank credit and therefore no debt covenant compliance requirements 2.
Weaknesses
Opportunities
- Rising demand for fire-resistant doors and smart systems could open new product categories 1.
- The proposed merger with FNRG could change the company's profile if completed before the agreed deadline 3.
- Expansion in Southeast Asia through the US foam partnership could widen the geographic sales area 1.
Threats
Risks
- Going concernhigh
Management has flagged substantial doubt about the company's ability to continue as a going concern, with liquidity expected into the first quarter of 2027 2.
- Customer concentrationhigh
A small number of customers generate most revenue without long-term contracts, which could materially hurt results if one of them withdraws 1.
- Dilution from new issuanceshigh
Funding through new or convertible shares could significantly reduce the stakes of existing shareholders 12.
- International and currency exposuremedium
Operating in Malaysia exposes the company to currency fluctuations, limits on repatriating funds and changes in tax rules 1.
- FNRG mergermedium
Completion depends on conditions not yet satisfied, and the agreed deadline could lead to termination of the agreement 3.
Investment thesis
What would need to be true (bull case)
- If Fitters' distribution business expands and margins hold, the group could become profitable, in line with management's expectations 2.
- The Malaysian fire protection market is growing steadily, and stricter rules could support long-term demand 1.
- If the FNRG transaction closes, the company could gain a new operating business and access to additional capital 3.
What would break the thesis
- The company could run out of sufficient capital before becoming profitable, which could lead to a scaling back of operations or bankruptcy, as its filing warns 2.
- Revenue is small relative to accumulated losses, and dependence on a few customers could amplify volatility in results 12.
- If the FNRG merger does not close, the company could remain in a fragile structure with insufficient funding 3.
What to watch
- Completion or termination of the FNRG mergerby 31 December 2026
- Revenue and gross margin of the distribution segmentQ3 2026
- New financing or strategic transactions supporting going concernQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company was previously known as Cyclacel Pharmaceuticals and ceased its pharmaceutical development business after the liquidation of its UK subsidiary Cyclacel Limited. Since September 2025, following the acquisition of Fitters Sdn. Bhd., its main activity has been supplying and trading fire protection equipment and solutions for commercial, industrial, healthcare and residential clients. Revenue was 0.7 million dollars for 2025 from the acquisition date 1.
The product range includes fire extinguishers, foam systems, fire-resistant doors under the PYRODOR brand and personal protective equipment, as well as fire-retardant apparel. The company states its products are approved by BOMBA and certified by SIRIM, pointing to a focus on compliance with local regulations 1.
The legal structure changed several times in 2025, with changes of control, reverse stock splits and issuances of preferred stock. In June 2026 the company disclosed a merger agreement under which FNRG shareholders would own more than 99% of the combined company, while existing shareholders would own less than 1% 23.
Segments
Fire protection equipment distribution
This is the main operating segment, with product revenue of 336 thousand dollars in the second quarter of 2026 and a gross margin of approximately 23% 3. Customers are concentrated: the top four accounted for 55% of 2025 sales 1.
Fire-retardant apparel and personal protective equipment
This segment includes fire-retardant clothing for the oil and gas industry and other high-risk sectors, as well as personal protective equipment distributed by the company 1. The sources analysed give no separate revenue figure for this segment.
Market context
The Malaysian fire safety equipment market is estimated at 1.1 billion dollars, based on a five-year historical analysis, with projected annual growth of 7% to 8% through 2030 1. Key drivers are stricter regulation, urbanisation and growing safety awareness. The Malaysian economy expanded 4.9% in 2025, supporting construction and industrial demand 1.
Trends
- Stricter regulationtailwind
Tighter enforcement of the Fire Services Act and building by-laws could increase demand for certified equipment, including fire-resistant doors 1.
- Urbanisation and infrastructuretailwind
Rapid urban development and projects in data centres and logistics could generate demand for specialised protection systems 1.
- Fire Safety 4.0 technologiesmixed
IoT-connected and eco-friendly solutions could require adaptation investment, which might call for additional capital from the company 1.
- Tariffs and trade policyheadwind
Changes in tariffs and trade restrictions by the US and other countries could affect supply costs and exports 1.
Competitive position
The sources note that barriers to entry for fire equipment distributors are low, meaning competition from local and international producers. Competitors may develop more advanced technology and gain market share 1.
The company mentions an agreement with CHEMGUARD (USA) to operate a foam blending facility serving Southeast Asia, an important strategic link but also a dependence on an external partner 1.
- CHEMGUARD
US-based maker of foam systems for fire protection, with which the company has an agreement to operate a blending facility in Malaysia 1.
- Local fire equipment manufacturers
The sources refer to local and international competitors supplying protection systems without naming them 1.
- International protection system distributors
Companies that can enter the market with imported products create competitive pressure, as described in the company's risk factors 1.
- Providers of smart detection systems
Companies offering IoT and automatic detection solutions could gain share in modern segments 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report04 Nov 2026Delisting notice · Financial statements and exhibits
- Current report16 Oct 2026Other events
- Quarterly report14 Aug 2026
- Current report14 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report01 Jul 2026Other events
- Current report22 Jun 2026Shareholder vote · Financial statements and exhibits
- Current report10 Jun 2026Material agreement · Item 3.02 · Financial statements and exhibits
- Current report04 Jun 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report15 May 2026
- Current report14 May 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Bio Green Med Solution, Inc. · 30 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Bio Green Med Solution, Inc. · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Bio Green Med Solution, Inc. · 14 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.